BioCentury | Feb 25, 2010
Targets & Mechanisms

Kinase double shot

...inhibitor that selectively hits one of each drug's many targets: RAF and PDGFRB . 1 Kinagen Inc....
...team, led by David Cheresh, vice chair of pathology at the university and cofounder of Kinagen...
...3 ( see Box 1, "Targeting the allosteric over the active site" ). Moving forward Kinagen...
BioCentury | Feb 18, 2010
Distillery Therapeutics

Indication: Indication

...with vehicle control. Next steps include studying the dual inhibitor in other preclinical cancer models. Kinagen Inc.'s...
...treat cancer. SciBX 3(7); doi:10.1038/scibx.2010.212 Published online Feb. 18, 2010 Findings patented; exclusively licensed to Kinagen...
Items per page:
1 - 2 of 2
BioCentury | Feb 25, 2010
Targets & Mechanisms

Kinase double shot

...inhibitor that selectively hits one of each drug's many targets: RAF and PDGFRB . 1 Kinagen Inc....
...team, led by David Cheresh, vice chair of pathology at the university and cofounder of Kinagen...
...3 ( see Box 1, "Targeting the allosteric over the active site" ). Moving forward Kinagen...
BioCentury | Feb 18, 2010
Distillery Therapeutics

Indication: Indication

...with vehicle control. Next steps include studying the dual inhibitor in other preclinical cancer models. Kinagen Inc.'s...
...treat cancer. SciBX 3(7); doi:10.1038/scibx.2010.212 Published online Feb. 18, 2010 Findings patented; exclusively licensed to Kinagen...
Items per page:
1 - 2 of 2